Abstract: The subject invention concerns a novel process for preparing novel N-oxide compounds of O-.beta.-D-glucuronides of an anticholinergic compound containing a tertiary nitrogen. Examples of suitable glucuronide starting materials are O-.beta.-D-glucuronides of tropicamide, scopolamine, atropine, hyoscyamine, and the like. The novel process gives high yields of the desired N-oxides which are useful as UV filters.
Abstract: Novel antibiotic U-64,864 producible in a fermentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces braegensis Dietz sp.n., NRRL 12567. This antibiotic is active against various Gram-positive bacteria, for example, Staphylococcus aureus, Streptococcus pyogenes and Streptococcus pneumoniae. Thus, antibiotic U-64,864 can be used in various environments to eradicate or control such bacteria.
Type:
Grant
Filed:
September 2, 1982
Date of Patent:
September 25, 1984
Assignee:
The Upjohn Company
Inventors:
Lester A. Dolak, Fritz Reusser, Thomas M. Castle, Betty R. Hannon, Alice L. Laborde, Charles K. Marschke
Abstract: An in vitro enzymatic process which efficiently converts ester-containing anticholinergics having a primary alcohol to their corresponding novel O-glucuronic acid derivatives. These novel glucuronides are useful as antiperspirants.
Abstract: Novel and useful ribonucleotides of analogs of the well known antibiotics lincomycin and clindamycin. These ribonucleotides are unexpectedly highly active against Streptococcus hemolyticus and Staphylococcus aureus in vivo.
Type:
Grant
Filed:
February 18, 1983
Date of Patent:
August 7, 1984
Assignee:
The Upjohn Company
Inventors:
Alexander D. Argoudelis, David W. Stroman
Abstract: Novel antibiotic U-64,815 producible in a fermentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces microspinus, NRRL 12524. This antibiotic is active against various Gram-positive bacteria, for example, Staphylococcus aureus. It is also active against Haemophilus influenzae. Thus, antibiotic U-64,815 can be used in various environments to eradicate or control such bacteria.
Type:
Grant
Filed:
September 29, 1982
Date of Patent:
June 12, 1984
Assignee:
The Upjohn Company
Inventors:
Howard A. Whaley, William C. Snyder, John C. Greenfield, John H. Coats
Abstract: Novel antibacterially-active analogs of the antibiotics nodusmicin and nargenicin A.sub.1. These compounds are prepared by selectively blocking active hydroxyl groups at the 9, 11 and 18 positions of nodusmicin, and the 11 and 18 positions of nargenicin A.sub.1. Antibacterially-active compounds can be used in various environments to control or eradicate susceptible bacteria. The techniques for such use are well known in the art.
Abstract: A process for expression of the gene for bovine growth hormone in the yeast Saccharomyces cerevisiae. Bovine growth hormone can be used to increase milk production in cows.
Abstract: An in vitro enzymatic process which efficiently converts (+,-)-tropicamide to essentially pure (+), (-)-tropicamide O-.beta.-D-glucuronide. This product is then separated, advantageously, into the novel compounds (+)-tropicamide O-.beta.-D-glucuronide and (-)-tropicamide O-.beta.-D-glucuronide. The products disclosed herein absorb ultraviolet light, and, thus, can be incorporated into suitable plastic films which are then useful for screening out harmful ultraviolet radiation for the protection of packaged goods. Also the products can be used to protect the skin against burning by sunlight.
Abstract: The subject invention concerns a novel fermentation process for making the useful steroid intermediate 24-nor-1,4-choladiene-3,22-dione (I). Compound (I) can be converted to valuable corticoids by known methods.
Abstract: Novel antibacterially-active compound, 1,2,8,8a-cyclopropa[c]benzo[1,2-b:-4,3-b']dipyrol-4(5H)-one, prepared by a novel chemical process. This compound, as well as antibacterially-active intermediates, can be used to eradicate or control susceptible bacteria, for example, B. subtilis, K. pneumonia, S. lutea, S. aureus, and M. avium.Claimed compounds include those of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined hereinafter.
Abstract: Novel and useful ribonucleotides of analogs of the well known antibiotics lincomycin and clindamycin. These ribonucleotides are unexpectedly highly active against Streptococcus hemolyticus and Staphylococcus aureus in vivo. These ribonucleotides are prepared by using resting cell or cell-free extracts of Streptomyces rochei, NRRL 3533, or cell-free extracts of Streptomyces coelicolor, NRRL 3532.
Type:
Grant
Filed:
September 17, 1982
Date of Patent:
February 7, 1984
Assignee:
The Upjohn Company
Inventors:
Tom E. Patt, Alexander D. Argoudelis, Vincent P. Marshall
Abstract: A process for expression of a gene, foreign to the host organism, coding for a protein in a suitable vehicle which comprises taking said gene and fusing it in the correct orientation relative to a transcriptional initiation region present in said vehicle, and inserting said vehicle into a eukaryotic host. Via the subject process, the gene for chicken ovalbumin is expressed in the yeast Saccharomyces cerevisiae. Chicken ovalbumin can be used in the food, i.e., baking, industry and also as a protein supplement for animals.
Abstract: The subject invention concerns a novel one-stage fermentation process for making the useful steroid intermediate 9-hydroxy-3-oxo-4,17(20)-pregnadiene-20-carboxylic acid (I). This process is significantly superior to the best prior art process known for making (I).
Type:
Grant
Filed:
May 11, 1981
Date of Patent:
January 31, 1984
Assignee:
The Upjohn Company
Inventors:
Merle G. Wovcha, John C. Knight, Alfred B. Garcia
Abstract: Novel antibiotic U-64,815 producible in a fermentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces microspinus, NRRL 12524. This antibiotic is active against various Gram-positive bacteria, for example, Staphylococcus aureus. It is also active against Haemophilus influenzae. Thus, antibiotic U-64,815 can be used in various environments to eradicate or control such bacteria.
Type:
Grant
Filed:
September 21, 1981
Date of Patent:
January 24, 1984
Assignee:
The Upjohn Company
Inventors:
Howard A. Whaley, William C. Snyder, John C. Greenfield, John H. Coats
Abstract: The subject invention concerns a novel fermentation process for making the novel useful steroid intermediate 9-hydroxy-3-oxo-4,17(20)-pregnadiene-20-carboxyaldehyde (I). This compound can be used as in the synthesis of valuable corticoids.
Abstract: Novel antibacterially active compound, 1,2,8,8a-cyclopropa?c!benzo?1,2-b:-4,3-b'!dipyrrol-4(5H)-one, prepared by a novel chemical process. This compound, as well as antibacterially-active intermediates, can be used to eradicate or control susceptible bacteria, for example B. subtilis, K. pneumonia, S. lutea, S. aureus, and M. avium.
Abstract: Novel antibacterially-active compound, 1,2,8,8a-cyclopropa[ c]-benzo[1,2-b:-4,3-b']dipyrol-4(5H)-one, prepared by a novel chemical process. This compound, as well as antibacterially-active intermediates, can be used to eradicate or control susceptible bacteria, for example, B. subtilis, K. pneumonia, S. lutea, S. aureus, and M. avium.
Abstract: The subject invention concerns a novel fermentation process for making the useful steroid intermediate 24-nor-1,4-choladiene-3,22-dione (I). Compound (I) can be converted to valuable corticoids by known methods.
Abstract: Novel antibacterially-active compound, 1,2,8,8a-cyclopropa[c]benzo[1,2-b:-4,3-b']dipyrol-4(5H)-one, prepared by a novel chemical process. This compound, as well as antibacterially-active intermediates, can be used to eradicate or control susceptible bacteria, for example, B. subtilis, K. pneumonia, S. lutea, S. aureus, and M. avium.Included is a process for the preparation of an intermediate compound of the formula ##STR1## wherein R.sub.2, R.sub.3 and R.sub.4 are as defined hereinafter.
Abstract: Novel antibacterially-active compound, 1,2,8,8a-cyclopropa[c]benzo[1,2-b:-4,3-b']dipyrol-4(5H)-one, prepared by a novel chemical process. This compound, as well as antibacterially-active intermediates, can be used to eradicate or control susceptible bacteria, for example, B. subtilis, K. pneumonia, S. lutea, S. aureus, and M. avium.